+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Clinical experience of capecitabine in metastatic breast cancer



Clinical experience of capecitabine in metastatic breast cancer



European Journal of Cancer 38(Suppl. 2): S10-S14



Results from two phase II studies in metastatic breast cancer have shown that the novel, tumour-selective fluoropyrimidine capecitabine provides an effective and well tolerated therapy in patients with metastatic breast cancer failing or resistant to anthracycline and taxane therapy. Response rates of between 20 and 25% have been observed, with median survival of 12.2-12.6 months. In addition, there was an acceptable incidence of adverse events including diarrhoea and hand-foot syndrome, which can be controlled with a dose reduction. Promising results from two further randomised, phase II studies have indicated that capecitabine may also play a role in first- and second-line treatment of metastatic breast cancer. Capecitabine compared favourably with paclitaxel in anthracycline-resistant patients and with intravenous (i.v.) CMF (cyclophosphamide/methotrexate/5-fluorouracil (5-FU)) in post-menopausal women who had received no prior chemotherapy for metastatic disease, with high efficacy and good tolerability. The results of these four phase II studies demonstrate that capecitabine is active and well tolerated in a range of settings for metastatic breast cancer.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 010330258

Download citation: RISBibTeXText

PMID: 11841930

DOI: 10.1016/s0959-8049(01)00416-6


Related references

Weekly Paclitaxel plus Capecitabine versus Docetaxel Every 3 Weeks plus Capecitabine in Metastatic Breast Cancer. Journal of Oncology 2012: 862921, 2012

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer. Journal of Clinical Oncology 24(18_Suppl): 10727-10727, 2016

Clinical efficacy of capecitabine and cyclophosphamide (XC) in patients with metastatic breast cancer. Acta Medica Okayama 65(4): 231-237, 2012

Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?. Breast 16(4): 420-424, 2007

Capecitabine maintenance therapy following docetaxel/capecitabine combination treatment in patients with metastatic breast cancer. Oncology Letters 10(4): 2598-2602, 2015

Oral capecitabine monotherapy in taxane anthracycline pre-treated metastatic breast cancer Suffolk Oncology Centre experience. EJC Suppl.s 1(5): S140, 2003

Lapatinib plus capecitabine versus capecitabine alone for ErbB2-positive metastatic breast cancer (MBC) Quality of Life (QOL) assessment. European Journal of Cancer Suppl.s 6(7): 216-217, 2008

Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. Breast Cancer Research and Treatment 117(3): 577-589, 2009

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Annals of Oncology 16(8): 1289-1296, 2005

Capecitabine plus docetaxel (XT): A first line, phase II clinical trial in metastatic breast cancer. Journal of Clinical Oncology 24(18_Suppl): 10624-10624, 2016

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. Journal of Clinical Oncology 23(4): 792-799, 2005

First-line chemotherapy with docetaxel plus capecitabine followed by capecitabine or hormone maintenance therapy for the treatment of metastatic breast cancer patients. Oncology Letters 9(2): 987-993, 2015

Effect of lapatinib plus capecitabine (L+C) on quality of life (QOL) compared to capecitabine (C) alone in ErbB2+ metastatic breast cancer (MBC): An exploratory analysis. Journal of Clinical Oncology 26(15_Suppl): 9532-9532, 2016

Ixabepilone plus capecitabine with capecitabine alone for metastatic breast cancer. Future Oncology 6(2): 201-207, 2010

Single-agent capecitabine maintenance therapy after response to capecitabine-based combination chemotherapy in patients with metastatic breast cancer. Anti-Cancer Drugs 23(7): 718-723, 2012